Skip to main content
Equibles
NVCR logo

NVCR · NovoCure Ltd

Track NVCR — free Ask ALVIS about NVCR
$15.19 -1.12 (-6.87%)
Market Cap
$1.90B
Shares
116.45M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$16.31 Open$16.96 Day$16.16–17.00 52W$9.82–20.55 Avg vol 30d1.9M Short int11.5M · 9.8% float · 7.5d Short vol51% Last earningsJul 23, 2026 DataJan 2020–Jul 2026 Filing10-Q · Jul 23

Up next

Next earnings call
Oct 22, 2026 Est · unconfirmed · in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Jul 23, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 18.2 · elevated Equity put/call 0.71
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +19%
      above
      Price vs 50-day avg −2%
      below
      RSI (14) 49
      neutral
      MACD trend Positive
      52-week position 60%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Strong
      1-month return +6%
      trailing
      6-month return +34%
      trailing
      YTD return +26%
      this year
      Relative strength +26%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $17 › 200d $14 — 50d above 200d
      Institutional flow Distributing
      40 of 224 funds reported for Jun 30 · net -28.8K sh shares · +4 new
      Insider flow Distributing
      Net -$939.7K over 90 days · 100% sells
      Short interest Falling
      9.84% of float · ▼ -3.6% MoM · 7.5 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr low
      224 holders — near 3-yr low, contrarian setup
      Squeeze score 68
      elevated · 0–100
      Fundamentals
      Strong
      Revenue growth +8%
      Y/Y
      Gross margin 75%
      contracting
      EPS growth +22%
      Y/Y
      Free cash flow $-75.7M
      Balance sheet $101.5M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 81%
      annualized · 1-yr
      Max drawdown −33%
      past year
      ATR 7.8%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed Jul 23, 2026
      Total net revenue · full year 2026 Initiated $710M – $725M
      prior FY $655.35M midpoint +9.5% Y/Y
      Net revenue contribution from Optune Lua and Optune Pax · full year 2026 Initiated $20M – $30M

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      0 · 5 · 2
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +19% Bullish
      Price vs 50-day avg
      −2% Neutral
      RSI (14)
      49 Neutral
      MACD trend
      Positive Bullish
      52-week position
      60% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bearish · 2 of 6
      Trend (MA cross) No cross
      50d $17 › 200d $14 — 50d above 200d
      Institutional flow Distributing
      40 of 224 funds reported for Jun 30 · net -28.8K sh shares · +4 new
      Insider flow Distributing
      Net -$939.7K over 90 days · 100% sells
      Short interest Falling
      9.84% of float · ▼ -3.6% MoM · 7.5 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr low
      224 holders — near 3-yr low, contrarian setup
      Price context
      position in its 52-week range
      52-wk low $10 Now $16 · 60% 52-wk high $21
      vs 200-day avg +19% vs 50-day avg -2%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      Active patients on Optune Gio in France 471 Q2 2026 —
      Active patients on Optune Gio in Germany 637 Q2 2026 —
      Active patients on Optune Gio in Japan 553 Q2 2026 —
      Active patients on Optune Gio in other active markets 634 Q2 2026 —
      Active patients on Optune Gio in the U.S. 2,341 Q2 2026 —
      Active patients on Optune Lua in France 1 Q2 2026 —
      Active patients on Optune Lua in Germany 38 Q2 2026 —
      Active patients on Optune Lua in Japan 64 Q2 2026 —
      Active patients on Optune Lua in other active markets 5 Q2 2026 —
      Active patients on Optune Lua in the U.S. 99 Q2 2026 —
      Active Optune Lua patients on therapy for the treatment of MPM 34 as of December 31, 2025 —
      Active Optune Lua patients on therapy for the treatment of NSCLC 122 as of December 31, 2025 —
      Optune Gio prescriptions received for the treatment of GBM 1,609 fourth quarter —
      Optune Lua prescriptions received for the treatment of MPM 27 fourth quarter —
      Optune Lua prescriptions received for the treatment of NSCLC 118 fourth quarter —
      Total Optune Lua prescriptions received 145 fourth quarter —

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Medical Devices — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      NVCR
      NovoCure Ltd
      this stock
      		$1.90B +26.1% +21.8% — 9.8%
      ABT
      Abbott Laboratories
      		 $186.84B -13.9% +5.7% 30.1 1.4%
      SYK
      Stryker Corp
      		 $132.87B -1.1% +11.2% 40.1 1.8%
      MDT
      Medtronic plc
      		 $111.21B -8.8% +8.4% 23.3 1.5%
      BSX
      Boston Scientific Corp
      		 $68.43B -51.7% +5.5% 19.3 1.9%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      222
      % held
      80.9%
      Reported
      40 of 224
      Top holder
      FMR LLC
      Held Float
      View
      Held by Funds
      Fund positions
      71
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      11.5M
      Days to cover
      7.5d
      Change
      -424.2K sh
      View
      Short Volume
      Short vol %
      51%
      As of
      Jul 29, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      161
      Value
      $2.9K
      As of
      Jun 15, 2026
      View
      Off-Exchange
      Off-exchange %
      37.2%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$939.7K
      Buyers / Sellers
      0 / 8
      Buyers Sellers
      View
      Congressional Trades Buy
      Member
      Marie Newman
      Amount
      $15.0K–$50.0K
      Traded
      Jul 2, 2021
      View
      Financials
      Financials
      Revenue (FY)
      $655.4M
      Net income (FY)
      $-136.2M
      EPS diluted
      $-1.22
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jul 23, 2026
      This year
      17
      View
      Proposed Sales
      Value
      $608.6K
      Shares
      39.1K
      Filed
      Jul 23, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jul 23, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      NVCR +2.3% +5.7% +33.8% +7.7% +26.1%
      SPY -1.0% 0.0% +7.4% -0.8% +8.6%
      vs SPY +3.3% +5.7% +26.4% +8.5% +17.5%
      Key facts CIK 1645113 CUSIP G6674U108 13F (30d) 57 filings 34 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)